Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Eisai

< Previous 1 2 Next >
Lecanemab Receives Priority Review Status in Japan
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
Tickers ESALY
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
Tickers ESALY
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
From Eisai
Via ACN Newswire
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
From Eisai
Via JCN Newswire
Tickers ESALY
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
From Eisai
Via JCN Newswire
Tickers ESALY
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
From Eisai
Via ACN Newswire
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
From Eisai
Via ACN Newswire
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
From Eisai
Via ACN Newswire
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
From Eisai
Via ACN Newswire
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
From Eisai
Via ACN Newswire
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
From Eisai
Via ACN Newswire
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
From Eisai
Via ACN Newswire
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
From Eisai
Via ACN Newswire
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
From Eisai
Via ACN Newswire
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
From Eisai
Via ACN Newswire
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
From Eisai
Via ACN Newswire
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
From Eisai
Via ACN Newswire
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
From Eisai
Via ACN Newswire
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
From Eisai
Via ACN Newswire
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
From Eisai
Via ACN Newswire
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
From Eisai
Via ACN Newswire
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
From Eisai
Via ACN Newswire
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
From Eisai
Via ACN Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.